We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Despite a strong cash position and a Takeda partnership elsewhere, the ...

On Tuesday, Keros Therapeutics (NASDAQ:KROS) faced a downgrade in stock rating from Buy to Neutral by Cantor Fitzgerald. The stock, which has declined nearly 80% over the past year according to ...

On Thursday, Oppenheimer adjusted its price target on Keros Therapeutics (NASDAQ:KROS) shares, reducing it significantly to $23.00 from the previous target of $63.00. The stock, currently trading ...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to safety concerns during a mid-stage trial, causing its shares to hit a ...

Keros Therapeutics has abandoned a phase 2 trial of its drug candidate for pulmonary arterial hypertension (PAH), cibotacept, after seeing evidence of potentially serious cardiovascular side effects.

During the last three months, 11 analysts shared their evaluations of Keros Therapeutics (NASDAQ:KROS), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...

LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros” or the "Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

For each presentation, an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of each event. About ...